查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948944

脊髓性肌肉萎縮症藥物市場依產品類型、治療類型和通路分類，全球預測（2026-2032年）

Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，脊髓性肌肉萎縮症治療市場價值將達到 65.4 億美元，到 2026 年將成長至 73.3 億美元，到 2032 年將達到 152.4 億美元，複合年成長率為 12.83%。

關鍵市場統計數據
基準年 2025 65.4億美元
預計年份：2026年 73.3億美元
預測年份 2032 152.4億美元
複合年成長率 (%) 12.83%

對當代脊髓性肌肉萎縮症 (SMA) 現狀的簡要概述：描述了臨床進展、治療路徑的轉變以及影響治療方案採納的相關人員的需求。

脊髓性肌肉萎縮症 (SMA) 已從一種無法治癒的遺傳性神經肌肉疾病轉變為一個高度動態的治療領域，這一領域受到分子創新、不斷演進的護理模式和日益激烈的商業性競爭的驅動。疾病修正治療的出現從根本上改變了臨床預期和治療路徑，促使臨床醫生、支付者和製造商重新思考早期診斷、長期追蹤和多學科管理等長期沿用的模式。本導言概述了目前 SMA 治療領域相關相關人員所面臨的背景，並從科學創新、可近性需求和服務提供方式的轉變三個面向展開後續分析。

本文將深入檢驗更快速的診斷、更多樣化的治療方法以及不斷發展的醫療服務模式如何共同重塑脊髓性肌肉萎縮症的生態系統。

脊髓性肌肉萎縮症 (SMA) 的治療模式正在經歷變革性變化，這不僅體現在單一治療方法的出現，也反映了診斷、臨床實踐和價值評估的系統性轉變。新生兒篩檢計畫的廣泛實施加速了無症狀病例的發現，從而催生了及時干預和長期監測的新臨床需求。診斷技術的進步也帶來了對可擴展治療模式的需求，並促使人們更加關注基因療法和系統療法的安全性監測。

對累積進口關稅和貿易政策趨勢如何改變 SMA 治療供應鏈、生產在地化和取得策略進行全面分析。

進口關稅和貿易措施相關的政策環境會對先進生物製藥、基因療法和特殊小分子藥物的供應和成本結構產生顯著的下游影響。如果對活性藥物原料藥、病毒載體或成品生物製藥徵收關稅或累積貿易措施，製造商可能面臨更高的生產成本和更複雜的跨境供應計劃。因此，相關人員需要評估關稅帶來的成本壓力將由製造商承擔、轉嫁給支付方和醫療服務提供方，還是透過強調風險分擔和長期採購協議的合約安排來緩解。

本文從詳細的細分觀點，闡述了產品模式、治療方法、通路和患者人口統計特徵如何影響臨床應用和服務設計。

細分市場分析揭示了不同產品類型、治療方式、通路和患者群體的顯著採用模式，這些模式決定了治療定位和商業性策略。就產品類型而言，市場可細分為反義寡核苷酸療法（以nusinersen為代表）、基因療法（例如onasemnogene abeparvovec）和小分子化合物（以risdiplam為代表）。每種治療方式都有其獨特的劑量、監測和​​療效持續時間，這會影響醫療服務提供者的工作流程和患者的偏好。就治療方法方式而言，市場涵蓋單藥療法和不斷發展的聯合治療，這引發了人們對治療順序、安全性重疊和累積效應等問題的思考。相關人員必須在臨床通訊協定和醫保報銷申請中解決這些問題。

分析決定全球主要地區准入途徑和策略重點的區域監管、報銷和基礎設施差異

脊髓性肌肉萎縮症 (SMA) 治療的區域趨勢受法規結構、報銷系統、醫療基礎設施成熟度以及診斷項目實施進度的影響。在美洲，強大的專科治療中心網路、成熟的支付方參與模式以及不斷擴展的新生兒篩檢計畫正在加速早期診斷和治療的普及，同時，報銷談判和准入計畫也在持續改進，以應對單劑量和慢性治療的高昂成本。同時，在歐洲、中東和非洲，相關人員面臨政策環境的差異，集中監管核准與各國不同的報銷途徑並存，導致不同地區的准入時間和過渡期協議結構存在差異。該地區的許多市場正著重將衛生技術評估結果與真實世界數據和患者報告結果相結合，以確保永續的報銷。

對製藥創新者、臨床機構和支持合作夥伴如何整合科學、生產和循證策略以確保永續獲取藥物進行策略分析。

SMA治療領域的關鍵相關人員將深厚的科研實力與生產規模、分銷能力以及在循證醫學方面的戰略投資相結合。領先的創新者憑藉著基因替代療法的先發優勢、成熟的反義療法臨床試驗計畫以及口服小分子藥物的持續最佳化而脫穎而出。這些機構正日益與契約製造製造商、臨床網路和患者權益組織建立跨領域合作關係，以滿足SMA治療的端到端需求，涵蓋從新生兒篩檢合作到長期療效夥伴關係的各個方面。

為製造商和醫療系統領導者提供實用的策略指導，以透過臨床差異化、供應鏈彈性和支付方合作來調整其價值提案。

產業領導者應採取多管齊下的策略，整合臨床差異化、切實可行的准入策略和穩健的供應鏈。首先，優先與新生兒篩檢和支付相關人員進行早期合作，將建立從診斷到治療啟動的協作路徑，減少延誤並提升早期療育的價值。其次，投資於能夠捕捉功能性結果、看護者負擔和長期安全性的真實世界證據項目，將增強價值提案並支持按績效付費的合約模式。第三，拓展靈活的醫療服務模式，包括家庭醫療保健支援、混合型專科診所和院內輸液中心，將在提升患者便利性的同時，確保對複雜治療進行臨床監督。

我們對混合調查方法進行了透明的解釋，該研究結合了專家訪談、系統文獻綜述和交叉檢驗，以確保分析的嚴謹性。

本分析整合了廣泛的一手和二手證據以及專家諮詢，以確保整體性和實用性。我們的調查方法包括對臨床專家、支付方顧問和供應鏈專業人員進行結構化訪談，以檢驗關於治療實施、管理複雜性和報銷動態的假設。同時，我們系統性地回顧了同儕審查文獻、監管申報文件和已發表的臨床試驗結果，以經過驗證的臨床數據檢驗治療方法說明和安全性考量。我們將定性研究結果與已記錄的監管措施和已發表的真實世界研究進行三角驗證，以解決差異並完善主題結論。

本文簡要概述了治療技術進步、系統準備和政策趨勢如何共同決定永續的醫療服務取得和長期的臨床效益。

研究結果表明，在當前的治療格局中，臨床創新與供應鏈、政策和支付方合作等因素緊密交織。分子療法的進步帶來了持續臨床效益的潛力，但要大規模實現這一潛力，需要協調投資於早期檢測、醫療服務提供者培訓、生產能力以及可靠的上市後證據。此外，關稅和報銷機制等政策槓桿會對藥物的可及性和商業性永續性重大影響，這凸顯了與相關人員積極對話和緊急時應對計畫的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 脊髓性肌肉萎縮症藥物市場（依產品類型分類）

  • 反義寡核苷酸
  • 基因治療
  • 低分子化合物

9. 脊髓性肌肉萎縮症藥物市場（依治療方法）

  • 聯合治療
  • 單藥治療

第10章 脊髓性肌肉萎縮症藥物市場（依通路分類）

  • 家庭醫療保健
  • 醫院藥房
  • 專科診所

第11章 脊髓性肌肉萎縮症藥物市場區域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 脊髓性肌肉萎縮症藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國脊髓性肌肉萎縮症藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國脊髓性肌肉萎縮症藥物市場

第15章：中國脊髓性肌肉萎縮症藥物市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc.
  • Audentes Therapeutics, Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Catalyst Pharmaceuticals, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Cytokinetics, Inc.
  • Genentech, Inc.
  • Genzyme Corporation
  • Ionis Pharmaceuticals, Inc.
  • NMD Pharma A/S
  • Novartis AG
  • Novartis Gene Therapies, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • REGENXBIO Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Scholar Rock, Inc.
Product Code: MRR-4F7A6D4FB8FC

The Drugs for Spinal Muscular Atrophy Market was valued at USD 6.54 billion in 2025 and is projected to grow to USD 7.33 billion in 2026, with a CAGR of 12.83%, reaching USD 15.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.54 billion
Estimated Year [2026] USD 7.33 billion
Forecast Year [2032] USD 15.24 billion
CAGR (%) 12.83%

A concise orientation to the modern spinal muscular atrophy environment explaining clinical advances, care pathway shifts, and stakeholder imperatives shaping therapeutic adoption

Spinal muscular atrophy (SMA) has moved from an untreatable genetic neuromuscular disorder to a highly active therapeutic landscape driven by molecular innovation, evolving care models, and intensified commercial dynamics. The advent of disease-modifying therapies has fundamentally altered clinical expectations and care pathways, prompting clinicians, payers, and manufacturers to reconsider long-standing paradigms around early diagnosis, long-term follow-up, and multi-disciplinary management. This introduction synthesizes the contemporary context for stakeholders entering or operating within the SMA therapeutic arena and frames the subsequent analysis in terms of scientific innovation, access imperatives, and service delivery transformation.

In recent years, the clinical community has shifted toward earlier identification through newborn screening and genetic diagnostics, enabling therapeutic interventions during pre-symptomatic or early symptomatic windows that correlate with improved motor outcomes. Simultaneously, advances in antisense oligonucleotide technology, adeno-associated viral vector gene replacement, and orally administered small molecules have created a tripartite therapeutic paradigm that presents both clinical opportunity and commercial complexity. As a result, healthcare systems are adapting reimbursement frameworks and developing specialized care delivery models to support chronic management, re-dosing considerations, and long-term safety surveillance.

Consequently, manufacturers and payers face new operational and strategic trade-offs. Investments in real-world evidence generation, outcome-based contracting, and patient support ecosystems have become essential to sustain favorable access. Meanwhile, clinicians and health systems must integrate multidisciplinary rehabilitation, respiratory support, and nutritional management into comprehensive care plans that optimize therapeutic benefit. Together, these shifts underscore the necessity for integrated stakeholder strategies that reconcile scientific promise with pragmatic delivery and sustainable access.

An in-depth examination of diagnostic acceleration, therapeutic diversification, and delivery model evolution that together have reshaped the spinal muscular atrophy ecosystem

The SMA landscape has experienced transformative shifts that go beyond the arrival of individual therapies, reflecting systemic changes in diagnostics, clinical practice, and value assessment. The widespread implementation of newborn screening programs has accelerated the detection of presymptomatic cases, creating a new clinical imperative to deliver timely intervention and longitudinal monitoring. This diagnostic momentum has, in turn, necessitated scalable treatment delivery models and intensified focus on safety monitoring for gene-based and systemic therapies.

Parallel to diagnostic advances, the therapeutic architecture has diversified into distinct mechanisms of action, prompting the emergence of combination strategies and comparative effectiveness inquiries. Payers and clinicians are demanding robust evidence that differentiates long-term functional outcomes, safety profiles, and durability of effect across antisense oligonucleotide therapies, gene replacement approaches, and orally administered small molecules. Consequently, manufacturers are investing in head-to-head and real-world studies while evolving their evidentiary packages to emphasize patient-centered outcomes and health economics metrics.

Moreover, the supply chain and delivery models for SMA therapies have adapted to accommodate high-cost, high-complexity treatments. Home healthcare services have grown in importance for administration and long-term monitoring, while specialty clinics and hospital pharmacies have evolved protocols for infusion, storage, and adverse event management. In addition, manufacturing capacity expansion, vector production scaling, and cold-chain logistics have become strategic priorities, influencing partnerships across contract development and manufacturing organizations, academic centers, and specialized distributors. These cumulative shifts illustrate an ecosystem moving from single-product introductions to sustained multi-stakeholder coordination focused on durable clinical benefit and equitable access.

A comprehensive analysis of how cumulative import duties and trade policy dynamics can alter supply chains, manufacturing localization, and access strategies in SMA therapeutics

The policy environment surrounding import duties and trade measures can have meaningful downstream effects on the availability and cost structure of advanced biologics, gene therapies, and specialized small molecules. In contexts where tariffs or cumulative trade measures are applied to active pharmaceutical ingredients, viral vectors, or finished biologic products, manufacturers may confront increased manufacturing costs and more complex cross-border supply planning. Consequently, stakeholders must evaluate whether tariff-induced cost pressures are absorbed by manufacturers, passed through to payers and providers, or mitigated through contractual arrangements that emphasize risk-sharing and long-term procurement agreements.

Beyond immediate pricing implications, tariffs can influence the geographic distribution of manufacturing investments and the strategic location of fill-finish or cold-chain operations. Firms may accelerate localization of select production steps or seek regional contract manufacturing partners to hedge against tariff exposure, which simultaneously affects lead times, quality oversight, and regulatory interactions. In addition, changes to import duty regimes can complicate inventory strategies and demand forecasting, particularly for one-time gene therapies that require tight synchronization between manufacturing slots and patient eligibility windows.

From a payer and health system perspective, cumulative tariff effects intersect with reimbursement negotiations and access policies. When cost bases shift, payers may revisit coverage criteria, prior authorization practices, and outcome-based contracting arrangements. As a result, manufacturers and health systems must collaborate more closely on data generation plans and risk-sharing mechanisms to ensure that patient access remains timely while aligning incentives across the care continuum. Ultimately, the interplay between trade policy and the SMA therapeutic landscape underscores the importance of proactive supply chain strategies, adaptive pricing models, and sustained engagement with regulators and payers to manage access and continuity of care.

A detailed segmentation-driven perspective explaining how product modality, therapeutic approach, distribution channels, and patient age cohorts shape clinical adoption and service design

Segmentation analysis reveals nuanced adoption patterns across product type, treatment modality, distribution channel, and patient age that frame therapeutic positioning and commercial approaches. When considering product type, the landscape divides into antisense oligonucleotide therapies exemplified by agents such as Nusinersen, gene therapies represented by products like Onasemnogene abeparvovec, and small molecules typified by Risdiplam; each modality carries distinct administration, monitoring, and durability profiles that influence provider workflows and patient preferences. In relation to treatment type, the market encompasses monotherapy approaches and evolving combination therapy regimens, prompting considerations around sequencing, safety overlap, and cumulative benefit that stakeholders must address in clinical protocols and reimbursement dossiers.

Distribution channel segmentation highlights divergent care delivery environments including home healthcare, hospital pharmacy, and specialty clinic settings, each of which imposes specific operational demands and patient experience implications. Home healthcare models emphasize remote monitoring, caregiver training, and decentralized administration capabilities, while hospital pharmacy and specialty clinic pathways necessitate institutional credentialing, infusion or procedural infrastructure, and tighter coordination with multidisciplinary teams. Age group segmentation further nuances demand and treatment choices, with adult patients often prioritizing maintenance of function and quality of life, older children and adolescents balancing developmental outcomes with therapy tolerability, and infants and toddlers demonstrating the greatest potential for disease modification when treated early. Together, these segmentation lenses inform targeted access strategies, tailored evidence generation, and differentiated patient support programming that refine commercial and clinical decision-making.

An analysis of regional regulatory, reimbursement, and infrastructure differences that determine access pathways and strategic priorities across major global territories

Geographic dynamics in SMA therapeutics are shaped by regulatory frameworks, reimbursement architectures, healthcare infrastructure maturity, and the pace of diagnostic program implementation. In the Americas, a robust network of specialized treatment centers, established payer engagement models, and expanding newborn screening programs have accelerated early diagnosis and treatment uptake, while reimbursement negotiations and access programs continue to evolve to address high-cost, one-time and chronic therapies. Meanwhile, in Europe, Middle East & Africa, stakeholders navigate a heterogeneous policy environment where centralized regulatory approvals coexist with diverse national reimbursement pathways, causing variation in time-to-access and the structure of managed entry agreements across jurisdictions. The emphasis in many markets within this region is on aligning health technology assessment outputs with real-world evidence and patient-reported outcomes to secure sustainable reimbursement.

Across the Asia-Pacific region, rapid capacity building in diagnostics and an increasing number of specialized clinical centers are enhancing detection and treatment opportunities, although disparities remain between urban tertiary centers and more resource-constrained areas. Policymakers and manufacturers are exploring scalable care models, local manufacturing partnerships, and tiered access programs to bridge these gaps, emphasizing capacity building for neonatal screening and clinical training. Taken together, these regional differences necessitate differentiated go-to-market strategies that consider regulatory timelines, payer negotiation styles, infrastructure readiness for administration and monitoring, and the cultural context of patient engagement and caregiving. Ultimately, geographic prioritization must balance short-term access wins with longer-term investments in local systems that support durable clinical benefit and equitable availability.

A strategic synthesis of how pharmaceutical innovators, clinical institutions, and supporting partners are aligning science, manufacturing, and evidence strategies to secure durable access

Leading stakeholders in SMA therapeutics combine deep scientific portfolios with strategic investments in manufacturing scale, distribution capabilities, and evidence generation. Key innovators have differentiated through first-mover advantages in gene replacement, established clinical trial programs for antisense modalities, and ongoing optimization of orally administered small molecule treatments. These organizations are increasingly forming cross-sector partnerships with contract manufacturers, clinical networks, and patient advocacy groups to address the end-to-end needs of SMA care, from newborn screening linkage to long-term outcomes monitoring.

At the same time, a cohort of specialized service providers and academic medical centers contributes essential infrastructure for clinical trials, natural history studies, and long-term safety registries. Collaboration across commercial developers and clinical institutions has accelerated learning around best practices for administration, adverse event mitigation, and rehabilitation protocols. Investors and corporate development teams are prioritizing assets and capabilities that enhance manufacturing predictability, broaden distribution networks, and strengthen real-world evidence generation, recognizing that sustained access depends on demonstrable long-term benefit, scalable logistics, and payer-aligned value propositions. As companies refine their competitive positioning, those that integrate clinical excellence, supply resiliency, and a credible outcomes evidence plan will be better positioned to navigate payer scrutiny and evolving care standards.

Action-oriented strategic guidance for manufacturers and health system leaders to align clinical differentiation, supply resilience, and payer-engaged value propositions

Industry leaders should adopt a multi-dimensional playbook that aligns clinical differentiation with pragmatic access strategies and resilient supply operations. First, prioritizing early engagement with newborn screening initiatives and payer stakeholders can create aligned pathways from diagnosis to treatment initiation, reducing delays and reinforcing the value of early intervention. Second, investing in real-world evidence programs that capture functional outcomes, caregiver burden, and long-term safety will strengthen value narratives and support outcome-based contracting approaches. Third, expanding flexible delivery models that encompass home healthcare support, hybrid specialty clinic scheduling, and hospital infusion capacity will improve patient convenience while safeguarding clinical oversight for complex therapies.

Additionally, manufacturers should diversify manufacturing footprints and explore regional partnerships to mitigate tariff exposure and logistic bottlenecks; concurrent investments in cold-chain robustness and contingency inventory planning will preserve treatment continuity for time-sensitive interventions. Commercial and medical affairs teams must also craft transparent pricing and contracting frameworks that permit swift payer negotiation while enabling access in lower-resource settings through tiered approaches or philanthropic partnerships. Finally, cross-sector collaboration with patient organizations and clinical networks will accelerate care pathway optimization and enhance adherence, patient education, and long-term follow-up-all of which are crucial to demonstrating real-world therapeutic value and reinforcing sustainable access models.

A transparent explanation of the mixed-method research approach integrating primary expert interviews, systematic literature review, and cross-validation to ensure analytical rigor

This analysis synthesizes evidence from a broad range of primary and secondary sources combined with expert consultations to ensure comprehensiveness and practical relevance. The research approach included structured interviews with clinical specialists, payer advisors, and supply chain experts to validate assumptions about treatment delivery, administration complexities, and reimbursement dynamics. In parallel, peer-reviewed literature, regulatory filings, and published clinical trial outcomes were systematically reviewed to ground therapeutic descriptions and safety considerations in verified clinical data. Triangulation of qualitative insights with documented regulatory actions and published real-world studies was employed to resolve discrepancies and to refine thematic conclusions.

To ensure methodological rigor, the research incorporated iterative validation cycles with external clinical advisors and cross-checked supply chain implications with manufacturing stakeholders. Limitations of the approach are acknowledged, particularly where long-term durability data remains emergent and where regional heterogeneity introduces variability in access timelines. Wherever possible, the analysis highlights evidence certainty and identifies areas where further primary data collection or prospective registries would materially improve confidence in long-term outcome projections. Ethical considerations guided the interview processes, and confidentiality agreements protected sensitive commercial insights provided by participating stakeholders.

A concise synthesis of how therapeutic advances, systems readiness, and policy dynamics converge to determine sustainable access and long-term clinical benefit

The cumulative insights point to a therapeutic environment in which clinical innovation is deeply interwoven with supply chain, policy, and payer engagement considerations. Advances in molecular therapies have created real potential for durable clinical benefit, but realizing that potential at scale requires coordinated investments in early detection, provider training, manufacturing capacity, and robust post-market evidence generation. Furthermore, policy instruments such as tariffs and reimbursement mechanisms can materially affect access timelines and commercial sustainability, highlighting the need for proactive stakeholder dialogue and contingency planning.

Going forward, the sector will likely see continued emphasis on data-driven value demonstration, expanded home-based care capabilities, and strategic partnerships that localize production and distribution where appropriate. Organizations that marshal clinical credibility, operational resilience, and payer-aligned evidence will be best placed to convert therapeutic promise into measurable patient outcomes at population scale. In sum, the current juncture presents both significant clinical opportunity and complex strategic challenges that require integrated, evidence-based responses from industry, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for Spinal Muscular Atrophy Market, by Product Type

  • 8.1. Antisense Oligonucleotide
  • 8.2. Gene Therapy
  • 8.3. Small Molecule

9. Drugs for Spinal Muscular Atrophy Market, by Treatment Type

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Drugs for Spinal Muscular Atrophy Market, by Distribution Channel

  • 10.1. Home Healthcare
  • 10.2. Hospital Pharmacy
  • 10.3. Specialty Clinic

11. Drugs for Spinal Muscular Atrophy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Drugs for Spinal Muscular Atrophy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Drugs for Spinal Muscular Atrophy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Drugs for Spinal Muscular Atrophy Market

15. China Drugs for Spinal Muscular Atrophy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Astellas Pharma Inc.
  • 16.6. Audentes Therapeutics, Inc.
  • 16.7. Biogen Inc.
  • 16.8. Biohaven Pharmaceutical Holding Company Ltd.
  • 16.9. Catalyst Pharmaceuticals, Inc.
  • 16.10. Chugai Pharmaceutical Co., Ltd.
  • 16.11. Cytokinetics, Inc.
  • 16.12. Genentech, Inc.
  • 16.13. Genzyme Corporation
  • 16.14. Ionis Pharmaceuticals, Inc.
  • 16.15. NMD Pharma A/S
  • 16.16. Novartis AG
  • 16.17. Novartis Gene Therapies, Inc.
  • 16.18. Pfizer Inc.
  • 16.19. PTC Therapeutics, Inc.
  • 16.20. REGENXBIO Inc.
  • 16.21. Roche Holding AG
  • 16.22. Sanofi S.A.
  • 16.23. Sarepta Therapeutics, Inc.
  • 16.24. Scholar Rock, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 31. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. NORTH AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. NORTH AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. NORTH AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. LATIN AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. LATIN AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. LATIN AMERICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. EUROPE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. MIDDLE EAST DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. MIDDLE EAST DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. MIDDLE EAST DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. ASEAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASEAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASEAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GCC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GCC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GCC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GCC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPEAN UNION DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPEAN UNION DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPEAN UNION DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. BRICS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. BRICS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. BRICS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. G7 DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. G7 DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. G7 DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. G7 DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NATO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NATO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NATO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NATO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)